Health and Healthcare

Amgen : AMGN

All Amgen Articles

720 Articles

Paul Ausick | Jul 30, 2015 at 4:26 PM EDT

Amgen Earnings Point to New 52-Week High

ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm…

Chris Lange | Jul 30, 2015 at 11:23 AM EDT

What to Expect from Amgen Earnings

ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates…

Chris Lange | Jul 27, 2015 at 7:57 AM EDT

Short Sellers Back Off Major Biotechs

ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of…

Jon C. Ogg | Jul 26, 2015 at 10:21 AM EDT

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings…

Lee Jackson | Jul 20, 2015 at 8:50 AM EDT

4 Large Cap Biotech Stocks to Buy Before Earnings

A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.

Chris Lange | Jul 13, 2015 at 7:55 AM EDT

Short Sellers Back Off Big Biotech

24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.

Lee Jackson | Jul 10, 2015 at 10:15 AM EDT

4 Defensive Stocks to Buy Now for Continued Market Volatility

None of these stocks are on the momentum traders' radar, and that is exactly what prudent growth investors need now.

Chris Lange | Jul 7, 2015 at 7:35 AM EDT

5 Big Upcoming FDA Decisions Expected in July

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and…

Chris Lange | Jun 25, 2015 at 7:50 AM EDT

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech…

Chris Lange | Jun 10, 2015 at 7:55 AM EDT

Short Sellers Lose Some Conviction Against Big Biotech

The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech…

Jon C. Ogg | Jun 7, 2015 at 9:40 AM EDT

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more…

Chris Lange | May 28, 2015 at 8:25 AM EDT

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of…

Jon C. Ogg | May 23, 2015 at 9:30 AM EDT

The Most Loved Biotechs of Big Hedge Funds

There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend…

Chris Lange | May 12, 2015 at 8:05 AM EDT

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks,…

Chris Lange | Apr 27, 2015 at 8:30 AM EDT

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech…

1 … 26 27 28 29 30 … 48

Amgen : AMGN

All Amgen Articles

Amgen Earnings Point to New 52-Week High

What to Expect from Amgen Earnings

Short Sellers Back Off Major Biotechs

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

4 Large Cap Biotech Stocks to Buy Before Earnings

Short Sellers Back Off Big Biotech

4 Defensive Stocks to Buy Now for Continued Market Volatility

5 Big Upcoming FDA Decisions Expected in July

Short Sellers Get More Selective on Big Biotech

Short Sellers Lose Some Conviction Against Big Biotech

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

Short Sellers Get Even More Ambitious Against Biotech Leaders

The Most Loved Biotechs of Big Hedge Funds

Short Sellers Start to Get Nervous on Biotech

Short Sellers Become More Wary of Big Biotech

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Amgen : AMGN

All Amgen Articles

Amgen Earnings Point to New 52-Week High

What to Expect from Amgen Earnings

Short Sellers Back Off Major Biotechs

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

4 Large Cap Biotech Stocks to Buy Before Earnings

Short Sellers Back Off Big Biotech

4 Defensive Stocks to Buy Now for Continued Market Volatility

5 Big Upcoming FDA Decisions Expected in July

Short Sellers Get More Selective on Big Biotech

Short Sellers Lose Some Conviction Against Big Biotech

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

Short Sellers Get Even More Ambitious Against Biotech Leaders

The Most Loved Biotechs of Big Hedge Funds

Short Sellers Start to Get Nervous on Biotech

Short Sellers Become More Wary of Big Biotech

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Featured Reads

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.